Malaria

P. falciparum Malaria: Developing a Synthetic Subunit Candidate Vaccine

Malaria is one of the most serious infectious diseases of humans, infecting 5–10% of the world’s population, with 300–600 million clinical cases and more than 2 million deaths annually. Moreover, malaria is a major social and economic burden in endemic areas. In recent years, malaria has spread at an alarming rate owing to the increasing resistance of the parasite to drugs, and the resistance of mosquitoes to insecticides. Therefore, new approaches to combat malaria are urgently needed, and a vaccine is predicted to have the greatest impact in addition to being the most cost-effective control measure.

Vaccine Development

One approach is to design a subunit vaccine that incorporates several malaria protein antigens for which there is evidence of protective immunity from epidemiological data or experimental animal challenge models. Development of such subunit vaccines is critically dependent on the availability of an antigen delivery system to drive suitable protein antigen-specific immune responses in humans. Vaccine formulations have to be highly effective, human-compatible and safe. Production of synthetic or recombinant proteins that stably mimic the native structure of the corresponding malaria antigens to induce effective humoral immune responses is a further major challenge.

Our research

We are addressing both problems by developing synthetic peptide structures that induce cross-reactive antibodies against the parent malaria proteins and by coupling them to the surface of immunopotentiating reconstituted influenza virosomes (IRIVs). In addition we are evaluating the use of so fare uncharacterized predicted proteins of Plasmodium falciparum as potential new candidate vaccine antigens.

Links

Accordini S et al. Incidence trends of airflow obstruction among European adults without asthma: a 20-year cohort study. Sci Rep. 2020;10:3452. DOI: 10.1038/s41598-020-60478-5

Adair T et al. Where there is no hospital: improving the notification of community deaths. BMC Med. 2020;18:65. DOI: 10.1186/s12916-020-01524-x

Aebi N.J, Bringolf-Isler B, Schaffner E, Caviezel S, Imboden M, Probst-Hensch N. Patterns of cross-sectional and predictive physical activity in Swiss adults aged 52+: results from the SAPALDIA cohort. Swiss Med Wkly. 2020;150:w20266. DOI: 10.4414/smw.2020.20266

Agrawala S et al. Call for comments: climate and clean air responses to covid-19. Int J Public Health. 2020(in press). DOI: 10.1007/s00038-020-01394-3

Ahenkorah S et al. Antimalarial N1,N3-dialkyldioxonaphthoimidazoliums: synthesis, biological activity, and structure-activity relationships. ACS Med Chem Lett. 2020;11:49-55. DOI: 10.1021/acsmedchemlett.9b00457

Ahmed N et al. The impact of rehabilitation-oriented virtual reality device in patients with ischemic stroke in the early subacute recovery phase: Study protocol for a phase III, single-blinded, randomized, controlled clinical trial. J Cent Nerv Syst Dis. 2020;12:1179573519899471. DOI: 10.1177/1179573519899471

Akoko J et al. Serological and molecular evidence of Brucella species in the rapidly growing pig sector in Kenya. BMC Vet Res. 2020;16:133. DOI: 10.1186/s12917-020-02346-y

Alinaitwe L, Kankya C, Namanya D, Pithua P, Dreyfus A. Leptospira seroprevalence among ugandan slaughter cattle: comparison of sero-status with renal Leptospira infection. Front Vet Sci. 2020;7:106. DOI: 10.3389/fvets.2020.00106

AlKhaldi M et al. Mapping stakeholders of the Palestinian Health Research System: a qualitative study. East Mediterr Health J. 2020;26(3):340-348. DOI: 10.26719/emhj.19.016

AlKhaldi M, Kaloti R, Shella D, Al Basuoni A, Meghari H. Health system's response to the COVID-19 pandemic in conflict settings: policy reflections from Palestine. Glob Public Health. 2020(in press). DOI: 10.1080/17441692.2020.1781914